Brazilian company GreenCare will start selling cannabis-based medicines medicinal directly on the market pharmaceutical starting in August, when prompt delivery will end the long wait for the medicine that is now imported directly by the patient.
Read more: Did you know that there are foods that can alter the effects of medications?
see more
Japanese company imposes time restriction and reaps benefits
Alert: THIS poisonous plant landed a young man in the hospital
Currently, the company and most of the market bring this type of medicine to individuals in Brazil from abroad. With 17 cannabis-based medicines, where they are produced by suppliers in Colombia, the United States and Israel.
They are stored in distribution centers outside the country, and arrive in Brazil through imports made by individuals, where they need to present authorization from Anvisa. It is estimated that the market has around 75,000 patients in Brazil, and the company already serves approximately 20,000. Once retail sales start, hopes are to double that amount by the end of 2023.
Talking about values, the importation of medicines today moves around BRL 250 million per year, according to information from the Brazilian Association of Cannabinoid Industry (BRCANN).
According to information from the company's President, Martim Prado Mattos, the company is already negotiating the sale of drugs at retail with about five pharmaceutical chains and already has a signed contract. GreenCare also has approval from Anvisa to market three drugs in pharmacies and is seeking authorization for three more by December 2022 and another four by 2023.
The products that are already approved for sale in pharmacies have cannabidiol and different concentrations of THC, a principle that has a psychoactive effect.
Lover of movies and series and everything that involves cinema. An active curious on the networks, always connected to information about the web.
